Congenital Heart Disease: The State-of-the-Art on Its Pharmacological Therapeutics

Area of Science:

• Cardiology
• Pharmacology
• Pediatrics

Background:

• Congenital heart disease (CHD) is a leading cause of death from malformations.
• While survival has improved, mortality remains significant, necessitating effective pharmacological interventions.
• Timely diagnosis and treatment are crucial for managing this time-sensitive condition.

Purpose of the Study:

• To analyze the applications, dosage, and side effects of current drugs used in treating congenital heart disease.
• To evaluate the impact of various pharmacological agents on patient outcomes and survival.
• To provide insights into optimizing drug therapy for congenital heart disease.

Main Methods:

• Comprehensive review of pharmacological interventions for congenital heart disease.
• Analysis of drug classes including ACE inhibitors, ARBs, beta-blockers, diuretics, and PAH-specific therapies.
• Evaluation of adjunctive symptomatic treatments like antiarrhythmics and NSAIDs.

Main Results:

• Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, and potassium-sparing diuretics demonstrate mortality benefits.
• Endothelin receptor antagonists, PDE-5 inhibitors, prostaglandins, and sGC stimulators benefit patients with pulmonary artery hypertension.
• Adjunctive therapies including antiarrhythmics, digoxin, and NSAIDs improve symptomatic outcomes.

Conclusions:

• Current pharmacotherapies offer significant benefits in survival and symptom management for congenital heart disease.
• Potential adverse effects like electrolyte imbalances and hemodynamic compromise exist but are often outweighed by benefits.
• Individualized patient assessment is essential for selecting the most beneficial therapeutic interventions.